Herceptin for HER2 breast cancer- targeted drug therapy

Although tremendous efforts are put in finding new therapeutic strategies and developing new screening programs to increase early diagnosis and treatment, breast cancer is still a significant cause of death in the worldwide female population. Human epidermal growth factor receptor type 2 (HER2) is a member of the epidermal growth factor, that initiates a variety of signalling pathways leading to cell proliferation and tumorigenesis, is a promising target in breast cancer therapy.

Some targeted therapy drugs that are directed at (target) proteins to prevent, treat and reduce the risk of breast cancer recurrence are monoclonal antibody like Trastuzumab (Herceptin). Trastuzumab is an antibody drug that specially target HER2-positive cancer cells. Trastuzumab attaches to the HER2 protein on the surface of HER2-positive breast cancer cells and slow/stop their growth.


Isolation of a monoclonal antibody named with high specificity towards HER


Trastuzumab approved in US for treatment of HER2 positive breast cancer


Trastuzumab approved in Europe


Trastuzumab approved for treatment in adjuvant of HER2 node positive breast cancer


Lapatinib approved for HER2 breast cancer


Trastuzumab emtansine was approved in USA breast cancer


Trastuzumab biosimilar Hertraz (MYL-14010) was approved in India and the trastuzumab biosimilar CT-P6 was approved in Korea


Trastuzumab was added to the South African Essential Medicines List (EML) in 2017 for the adjuvant management of HER2-positive early breast cancer.


Biosimilar agents currently approved in the European Union, the United States, and Canada Enoxaparin sodium (2017), Bevacizumab & Adalimumab (2017), Herzuma (2018), Ontruzant/ Trazimera/ Kanjinti (2019)


FDA approved a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin)


Enhertu approved in USA

Top patented combination of trastuzumab

Chemotherapy drugs
HER2-targeted monoclonal antibodies



Alkaloid derivative
Kinase inhibitor



Biosimilar of Trastuzumab

Trastuzumab Deruxtecan trials have introduced a new subtype of HER2 expressing metastatic breast cancer. Targeting and treating HER2-low breast cancer HER 2 low breast cancer, which represent at least 50% of breast cancer have raised new challenges. Unfortunately, the low HER2 expression failed to provide clinical prognosis benefits. The available HER2-targeted therapies are inefficient in HER2-low BC, and treatment options are restricted after the initial treatment progression. Despite the ineffectiveness of trastuzumab for HER2-low BC, the ability of ADCs to significantly improve prognosis has spurred interest in conventional targeted agents

Interested in Herceptin for HER2 breast cancer- targeted drug therapy ? Reach out to us.